10 recruiting, 3 not yet recruiting, 3 unknown, 2 active not recruiting. 9 Phase 2, 3 Phase 1, 3 Phase 3, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 4, Not yet recruiting 3, Completed 1, Unknown 1 |
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 3 | 3 | Recruiting 2, Unknown 1 |
| Not applicable | 2 | Active not recruiting 1, Recruiting 1 |
Follow EGFR: new trials by email Literature Review of EGFR trials Research Report on EGFR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC Zipalertinib - EGFR, Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Stanford University | 42 | 2026-11-01 | 2026-09-03 |
| Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC Firmonertinib combined anlotinib and chemotehrapy - NSCLC (Non-small Cell Lung Cancer), EGFR | Phase 2 | Not yet recruiting | Hubei Cancer Hospital | 29 | 2026-09-21 | 2026-09-08 |
| A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC EPI-326 - Epidermal Growth Factor, Epidermal Growth Factor Receptor | Phase 1 | Recruiting | EpiBiologics | 110 | 2026-03-31 | 2026-10-14 |
| A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection TAS6417, Zipalertinib Matching-placebo - Lung Cancer, Adjuvant | Phase 3 | Recruiting | Taiho Oncology, Inc. | 360 | 2025-12-22 | 2026-10-13 |
| Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Trilaciclib and Sacituzumab Tirumotecan - NSCLC (Advanced Non-small Cell Lung Cancer), EGFR | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 49 | 2025-12-08 | 2026-04-14 |
| The HER Project: HRD in EGFR-mutated NSCLC No Intervention: Observational Cohort - EGFR, Non Small Cell Lung Cancer | Active not recruiting | IRCCS San Raffaele | 100 | 2025-12-01 | 2025-12-31 | |
| Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC Fumetinib combined platinum-based double chemotherapy, Concurrent Radiochemotherapy - EGFR, NSCLC (Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Peng Zhang | 160 | 2025-11-25 | 2026-08-03 |
| Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic | Recruiting | GFPC Investigation | 100 | 2025-11-19 | 2026-05-01 | |
| Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer Surgery, Osimertinib - Non-Small Cell Lung Cancer, EGFR | Phase 2 | Not yet recruiting | Jianxing He | 118 | 2025-09-08 | 2025-09-16 |
| Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI Befotertinib, Pemetrexed + Carboplatin - NSCLC, Adjuvant Drug Therapy | Phase 2 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 28 | 2025-09-01 | 2025-09-30 |
| Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors VIR-5525, Pembrolizumab - Solid Tumor Malignancies, EGFR Positive Solid Tumors | Phase 1 | Recruiting | Vir Biotechnology, Inc. | 450 | 2025-07-22 | 2026-04-13 |
| Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery Salt substitute - Kidney Tumors, CKD | Not applicable | Recruiting | Jinling Hospital, China | 200 | 2025-04-24 | 2025-12-15 |
| Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation Firmonertinib Mesilate Tablets, Pemetrexed Disodium for Injection, Cisplatin for injection - EGFR, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 | Recruiting | Allist Pharmaceuticals, Inc. | 300 | 2024-11-19 | 2026-08-13 |
| Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy - EGFR, Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Peng Zhang | 60 | 2024-11-07 | 2025-01-06 |
| Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules Cetuximab-IRDye800 - Lung Cancer, Video-assisted Thoracic Surgery | Phase 2 | Unknown | University of Turin, Italy | 25 | 2024-01-01 | 2024-01-25 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors TT125-802 - Advanced Solid Tumor, Adult Solid Tumor | Phase 1 | Completed | TOLREMO therapeutics AG | 45 | 2023-11-07 | 2026-07-07 |
| Almonertinib Plus Metronomic Oral Vinorelbine Almonertinib and metronomic oral vinorelbine - EGFR, NSCLC | Unknown | Fujian Cancer Hospital | 40 | 2022-12-20 | 2022-12-23 | |
| Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies Sensus Smartwatch Application, RX Cap, Fitbit Sense - Lung Cancer, EGFR Gene Mutation | Not applicable | Active not recruiting | University of Virginia | 30 | 2022-08-25 | 2025-11-25 |
| To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma Gefitinib, Vinorelbine, Carboplatin - NSCLC, EGFR | Phase 3 | Unknown | Shenzhen People's Hospital | 48 | 2018-08-31 | 2018-09-04 |
| Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer BIBW 2992 - Non-Small Cell Lung Cancer, EGFR | Phase 2 | Completed | Instituto Nacional de Cancerologia de Mexico | 66 | 2012-01-01 | 2024-02-06 |
Carcinoma, Non-Small-Cell Lung (12) · Lung Neoplasms (5) · Carcinoma, Renal Cell (1) · Disease (1) · Head and Neck Neoplasms (1) · Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Neoplasms (15) · Neoplasms by Site (15) · Lung Diseases (14) · Respiratory Tract Diseases (14) · Respiratory Tract Neoplasms (14) · Thoracic Neoplasms (14) · Bronchial Neoplasms (12) · Carcinoma, Bronchogenic (12) · Lung Neoplasms (9) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Carcinoma, Squamous Cell (1) · Female Urogenital Diseases (1)
Carboplatin (3) · Pemetrexed (2) · zipalertinib (2) · Afatinib (1) · Cetuximab (1) · Chemoradiotherapy (1) · Cisplatin (1) · Gefitinib (1) · Injections (1) · Surgical Procedures, Operative (1) · Surveys and Questionnaires (1) · Vinorelbine (1) · aumolertinib (1) · osimertinib (1) · pembrolizumab (1)
Peng Zhang (2) · Allist Pharmaceuticals, Inc. (1) · Betta Pharmaceuticals Co., Ltd. (1) · EpiBiologics (1) · Fujian Cancer Hospital (1) · GFPC Investigation (1) · Hubei Cancer Hospital (1) · IRCCS San Raffaele (1) · Instituto Nacional de Cancerologia de Mexico (1) · Jianxing He (1) · Jinling Hospital, China (1) · Shenzhen People's Hospital (1) · Stanford University (1) · TOLREMO therapeutics AG (1) · Taiho Oncology, Inc. (1)
China (8) · United States (5) · Italy (3) · Australia (2) · France (2) · Mexico (2) · South Korea (2) · Spain (2) · Argentina (1) · Belgium (1) · Brazil (1) · Canada (1) · Germany (1) · Greece (1) · Hong Kong (1)
DongYing Liu (1) · Dr Thomas Pierret (1) · Enrico Ruffini, M.D. (1) · Francesca Rita Ogliari, Medical Doctor (1) · Francesco Guerrera, M.D., Ph.D. (1) · GuiNan Lin (1) · Joel Neal, MD (1) · Oscar Arrieta, MD M Sc (1) · Prof. Jean-Bernard Auliac (1) · Qiu Chen, Doctor (1) · Ryan Gentzler, MD (1) · Shaodong Hong (1) · XiaoFeng Pei (1)
2023 (1), 2025 (1)